These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1139 related articles for article (PubMed ID: 21960707)

  • 1. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.
    Dowsett M; Nielsen TO; A'Hern R; Bartlett J; Coombes RC; Cuzick J; Ellis M; Henry NL; Hugh JC; Lively T; McShane L; Paik S; Penault-Llorca F; Prudkin L; Regan M; Salter J; Sotiriou C; Smith IE; Viale G; Zujewski JA; Hayes DF;
    J Natl Cancer Inst; 2011 Nov; 103(22):1656-64. PubMed ID: 21960707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant endocrine therapy: Patient selection, treatment duration and surrogate endpoints.
    Yeo B; Dowsett M
    Breast; 2015 Nov; 24 Suppl 2():S78-83. PubMed ID: 26255746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
    Dowsett M; Smith IE; Ebbs SR; Dixon JM; Skene A; A'Hern R; Salter J; Detre S; Hills M; Walsh G;
    J Natl Cancer Inst; 2007 Jan; 99(2):167-70. PubMed ID: 17228000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
    Ellis MJ; Suman VJ; Hoog J; Goncalves R; Sanati S; Creighton CJ; DeSchryver K; Crouch E; Brink A; Watson M; Luo J; Tao Y; Barnes M; Dowsett M; Budd GT; Winer E; Silverman P; Esserman L; Carey L; Ma CX; Unzeitig G; Pluard T; Whitworth P; Babiera G; Guenther JM; Dayao Z; Ota D; Leitch M; Olson JA; Allred DC; Hunt K
    J Clin Oncol; 2017 Apr; 35(10):1061-1069. PubMed ID: 28045625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment.
    Fasching PA; Heusinger K; Haeberle L; Niklos M; Hein A; Bayer CM; Rauh C; Schulz-Wendtland R; Bani MR; Schrauder M; Kahmann L; Lux MP; Strehl JD; Hartmann A; Dimmler A; Beckmann MW; Wachter DL
    BMC Cancer; 2011 Nov; 11():486. PubMed ID: 22081974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Surrogate Markers of Treatment Activity: Where Are We Now?
    Klintman M; Dowsett M
    J Natl Cancer Inst Monogr; 2015 May; 2015(51):24-8. PubMed ID: 26063881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer.
    Zhang A; Wang X; Fan C; Mao X
    Front Endocrinol (Lausanne); 2021; 12():687244. PubMed ID: 34803903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
    Dowsett M; Ebbs SR; Dixon JM; Skene A; Griffith C; Boeddinghaus I; Salter J; Detre S; Hills M; Ashley S; Francis S; Walsh G; Smith IE
    J Clin Oncol; 2005 Apr; 23(11):2477-92. PubMed ID: 15767642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ki67 assessment in breast cancer: an update.
    Penault-Llorca F; Radosevic-Robin N
    Pathology; 2017 Feb; 49(2):166-171. PubMed ID: 28065411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re: Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
    Hrushesky WJ; Retsky M; Baum M; Demicheli R
    J Natl Cancer Inst; 2007 Jul; 99(13):1053; author reply 1053-4. PubMed ID: 17596578
    [No Abstract]   [Full Text] [Related]  

  • 13. High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer.
    Alba E; Lluch A; Ribelles N; Anton-Torres A; Sanchez-Rovira P; Albanell J; Calvo L; García-Asenjo JA; Palacios J; Chacon JI; Ruiz A; De la Haba-Rodriguez J; Segui-Palmer MA; Cirauqui B; Margeli M; Plazaola A; Barnadas A; Casas M; Caballero R; Carrasco E; Rojo F
    Oncologist; 2016 Feb; 21(2):150-5. PubMed ID: 26786263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An international Ki67 reproducibility study.
    Polley MY; Leung SC; McShane LM; Gao D; Hugh JC; Mastropasqua MG; Viale G; Zabaglo LA; Penault-Llorca F; Bartlett JM; Gown AM; Symmans WF; Piper T; Mehl E; Enos RA; Hayes DF; Dowsett M; Nielsen TO;
    J Natl Cancer Inst; 2013 Dec; 105(24):1897-906. PubMed ID: 24203987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting endocrine therapy responsiveness in breast cancer.
    Ma CX; Sanchez CG; Ellis MJ
    Oncology (Williston Park); 2009 Feb; 23(2):133-42. PubMed ID: 19323294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer.
    Jones RL; Salter J; A'Hern R; Nerurkar A; Parton M; Reis-Filho JS; Smith IE; Dowsett M
    Breast Cancer Res Treat; 2009 Jul; 116(1):53-68. PubMed ID: 18592370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010).
    Berruti A; Generali D; Kaufmann M; Puztai L; Curigliano G; Aglietta M; Gianni L; Miller WR; Untch M; Sotiriou C; Daidone M; Conte P; Kennedy D; Damia G; Petronini P; Di Cosimo S; Bruzzi P; Dowsett M; Desmedt C; Mansel RE; Olivetti L; Tondini C; Sapino A; Fenaroli P; Tortora G; Thorne H; Bertolini F; Ferrozzi F; Danova M; Tagliabue E; de Azambuja E; Makris A; Tampellini M; Dontu G; Van't Veer L; Harris AL; Fox SB; Dogliotti L; Bottini A
    J Natl Cancer Inst Monogr; 2011; 2011(43):147-51. PubMed ID: 22043063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.
    von Minckwitz G; Sinn HP; Raab G; Loibl S; Blohmer JU; Eidtmann H; Hilfrich J; Merkle E; Jackisch C; Costa SD; Caputo A; Kaufmann M;
    Breast Cancer Res; 2008; 10(2):R30. PubMed ID: 18380893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
    Luo J; Zhou Z; Yang Z; Chen X; Cheng J; Shao Z; Guo X; Tuan J; Fu X; Yu X
    Medicine (Baltimore); 2016 Feb; 95(8):e2914. PubMed ID: 26937935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
    Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C
    JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.